Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a common antibiotic beat syphilis?

NCT ID NCT05548426

Disease control Sponsor: University of Southern California Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether the antibiotic linezolid can effectively treat early syphilis in 24 adults. Participants have primary, secondary, or early latent syphilis, and some also have well-controlled HIV. The main goal is to see if linezolid reduces syphilis infection markers in the blood within 6 months.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 24 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2023

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

16 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: To be eligible for this study, participants must be: 1. Diagnosed cases of primary, secondary or early latent syphilis with RPR titer ≥1:8 within 3 weeks prior to enrollment 2. 16 years of age or older 3. Able to provide informed consent/assent. 4. Individuals with HIV infection must be on treatment for HIV-infection and virologically suppressed (viral load \< 200 copies/mL) or have a CD4 count ≥ 350 cells/mm3 as of their most recent test prior to enrollment. Exclusion Criteria include: 1. Pregnancy or a positive pregnancy test on the day of enrollment 2. Patients showing signs and symptoms of neurosyphilis. 3. Participants who receive certain psychotropic medications, e.g., MAO inhibitors, SNRIs, SSRIs 4. Serofast RPR titer, defined as persistently positive RPR titer without more than 4-fold (2-titer level) change for 12 months or greater. 5. Recent (within the past 7 days) or concomitant antimicrobial therapy with activity against syphilis, namely azithromycin, tetracycline, doxycycline, cefixime, ceftriaxone or other beta lactam antibiotics (e.g. amoxicillin) 6. Individuals with HIV infection who report HIV treatment interruption for more than 4 weeks since their most recent viral load or CD4 test. 7. Individuals with known myelosuppressive conditions or receiving myelosuppressive medication 8. Individuals weighing 150kg (330 lbs) or more. 9. Individuals with known end renal stage disease, for example individuals in hemodialysis. 10. Self-reported allergy to linezolid or penicillin. 11. Unwilling or unable to attend follow-up visits.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Syphilis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

syphilis Treponema infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Syphilis

Contacts and locations

Locations

  • Howard Brown Health

    Chicago, Illinois, 60613, United States

  • Open Arms HealthCare Center

    Jackson, Mississippi, 39216, United States

  • Open Door Health

    Providence, Rhode Island, 02907, United States

  • University of Mississippi Medical Center

    Jackson, Mississippi, 39216, United States

  • Wake Forest Baptist Health

    Greensboro, North Carolina, 27405, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.